project-idea

ImmunoComboDB: A Curated Database of CD4+ T Cell-Boosting + Checkpoint Inhibitor Combination Studies

An orally available small molecule (Alphataxin) that boosts tumor-infiltrating CD4+ T cells combined with anti-PD-1 achieved 37.5% objective response rate in colon cancer mice — significantly better than either monotherapy alone.

Checkpoint immunotherapy response is frequently limited not by the checkpoint axis itself but by insufficient CD4+ T helper cell support for CD8 killers. This paper is one of a growing number showing that boosting CD4+ T cell presence in tumors potentiates checkpoint therapy. ImmunoComboDB would aggregate all published preclinical and clinical studies testing the combination of immune priming agents (CD4+ T cell boosters, innate activators, vaccine adjuvants) with checkpoint inhibitors across cancer types.

The database would be structured around the 'priming agent' category — including small molecules, cytokines, vaccines, CAR-T cells, and biologics — paired with the checkpoint inhibitor used, the cancer type, and the outcome. Researchers could query: 'What agents have been combined with anti-PD-1 to boost CD4 T cells in colorectal cancer?' and get a systematic view of the evidence landscape.

A companion summary layer would identify gaps — cancer types or checkpoint combinations with no published priming agent data — and help researchers prioritize the most actionable combination experiments. This would be particularly valuable for translational investigators planning IND-enabling studies.

Who Is This For?

Immunotherapy researchers, translational oncologists, and biotech/pharma teams developing combination immunotherapy regimens.

Skills & Tools Needed

Database design and literature curation
Systematic review methodology
Web development
Cancer immunology knowledge
Data visualization (network graphs of combinations)

Feasibility

high — Primarily a literature curation and database project; the technical barrier is low, and the scientific literature base is well-defined and growing.

Inspired by: Antitrypsin surrogate, Alphataxin, increases tumor CD4+ T cells and suppresses murine colon cancer

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.